Business
10x Genomics Surpasses 100 Xenium Analyzer Shipments
Rapid growth and adoption of Xenium Analyzer demonstrates strength of company's innovation engine, broad commercial reach and operational scale PLEASANTON,
About this update from 10x Genomics, Inc.
[{"type":"text","content":"Rapid growth and adoption of Xenium Analyzer demonstrates strength of company's innovation engine, broad commercial reach and operational scale \nPLEASANTON, Calif., Aug. 29, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has shipped more than 100 Xenium Analyzer instruments in the eight months since the platform's launch. The milestone reflects strong customer demand for the Xenium platform, which is increasingly recognized as the best performing system for in situ analysis.\n\n \n \n \n \n \n \n\n \n\"We built Xenium so it 'just works' in the hands of researchers, and it's been so rewarding to have our early customers rave about the platform's ease of use, best-in-class performance and 'mind-blowing' data,\" said Serge Saxonov, Co-founder and CEO of 10x Genomics. \"I'm proud of our team for achieving this milestone so quickly, and we're still just getting started. I firmly believe Xenium has the potential to be one of the most transformative technologies in our industry in decades.\"\nWith the vast majority of the first 100 Xenium shipments already installed, researchers are using the system to successfully analyze a variety of tissues and sample types, including fresh frozen, FFPE and tissue microarrays, and reveal new insights into health and disease.\n\"The Xenium platform is providing us with unprecedented insight into the molecular pathology of disease at an incredible resolution,\" said Dr. Simon Gregory, Professor and Director of the Brain Tumor Omics Program in the Duke University Department of Neurosurgery and Director of the Molecular Genomics Core at the Duke Molecular Physiology Institute. To date, the Gregory Lab has analyzed more than 70 samples on the Xenium platform. \"Building on standard panels with custom content has allowed us to begin unraveling the mechanisms within tissues from human and model systems associated with a variety of neurological conditions, including primary and metastatic brain tumors, multiple sclerosis, and behavioral phenotypes in a detailed spatial context.\"\nDr. Bo Li, Senior Research Fellow at the Genome Institute of Singapore, said, \"Xenium is a state-of-the-art spatial-omics technology that enables researchers to spatially profile RNA transcripts at subcellular resolution within complex tissue systems. W...